A\u00a0NEW\u00a0phase 3 trial suggests that\u00a0mazdutide, a once-weekly dual glucagon and glucagon-like peptide-1 (GLP-1) receptor agonist, may offer enhanced glycaemic control and weight reduction compared with dulaglutide in adults with type 2 diabetes. The findings add to growing interest in multi-agonist therapies that target both glucose regulation and energy balance.\u00a0<\/p>\n
Mazdutide\u00a0has been developed to combine the established glucose-lowering effects of GLP-1 receptor agonism with glucagon-mediated effects on energy expenditure. In this randomised study, its efficacy and safety were evaluated against dulaglutide in people with type 2 diabetes receiving background oral anti-diabetic drugs.\u00a0<\/p>\n
Mazdutide\u00a0Shows Superior HbA1c Reduction<\/b>\u00a0<\/p>\n
The 28-week trial enrolled 731 participants, who were randomised to\u00a0mazdutide\u00a04 mg,\u00a0mazdutide\u00a06 mg, or dulaglutide 1.5 mg once weekly. Both doses of\u00a0mazdutide\u00a0met criteria for non-inferiority and\u00a0demonstrated\u00a0statistically significant superiority over dulaglutide in reducing HbA1c from baseline. Mean HbA1c reductions were greater with\u00a0mazdutide\u00a06 mg than with the 4 mg dose, suggesting a dose-response effect.\u00a0For clinicians, the absolute differences in HbA1c,\u00a0around 0.25\u20130.30 percentage points,\u00a0may appear modest, but they were consistent and accompanied by\u00a0additional\u00a0metabolic benefits.\u00a0<\/p>\n
Greater Weight Loss and Composite Outcomes<\/b>\u00a0<\/p>\n
Weight reduction was notably greater with\u00a0mazdutide\u00a0than with dulaglutide. Participants receiving\u00a0mazdutide\u00a0achieved mean\u00a0additional\u00a0weight losses of\u00a0approximately 4\u20136% compared with dulaglutide, with the higher dose again producing larger effects. Importantly, more participants treated with\u00a0mazdutide\u00a0reached a clinically relevant composite endpoint of HbA1c below 7.0% alongside at least 5% weight loss.\u00a0These combined outcomes reflect the dual-agonist mechanism and align with increasing emphasis on weight management as part of comprehensive type 2 diabetes care.\u00a0<\/p>\n
Safety Profile and Tolerability<\/b>\u00a0<\/p>\n
Mazdutide\u00a0was\u00a0generally well\u00a0tolerated over 28 weeks. Gastrointestinal adverse events,\u00a0most commonly diarrhoea, nausea, and vomiting,\u00a0were more frequent than with dulaglutide, consistent with other incretin-based therapies. Serious safety concerns were not highlighted in the study.\u00a0<\/p>\n
Putting the Findings in Context<\/b>\u00a0<\/p>\n